HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lynn Bonham Selected Research

2-acylglycerophosphate acyltransferase

11/2006Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
10/2006Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival.
8/2006Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia.
10/2005Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies.
7/2005Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
12/2003Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
10/2003Inhibition of lysophosphatidic acid acyltransferase beta disrupts proliferative and survival signals in normal cells and induces apoptosis of tumor cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lynn Bonham Research Topics

Disease

7Neoplasms (Cancer)
11/2014 - 10/2003
2Leukemia
11/2006 - 08/2006
2Ovarian Neoplasms (Ovarian Cancer)
10/2006 - 10/2005
2Multiple Myeloma
04/2005 - 12/2003
1Breast Neoplasms (Breast Cancer)
11/2014
1Graft vs Host Disease (Graft-Versus-Host Disease)
11/2010
1Inflammation (Inflammations)
11/2010
1Peritonitis
11/2010
1Pneumonia (Pneumonitis)
11/2010
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
11/2006
1Ovarian Epithelial Carcinoma
10/2006
1Ascites
10/2005
1Endometrial Neoplasms (Endometrial Cancer)
10/2005
1Non-Hodgkin Lymphoma (Lymphosarcoma)
07/2005
1Lymphoma (Lymphomas)
07/2005
1Necrosis
04/2005
1Carcinogenesis
10/2003

Drug/Important Bio-Agent (IBA)

72-acylglycerophosphate acyltransferaseIBA
11/2006 - 10/2003
3Protein Isoforms (Isoforms)IBA
08/2006 - 10/2003
2CT-32228IBA
08/2006 - 07/2005
2lysophosphatidic acidIBA
10/2005 - 12/2003
2Phosphatidic Acids (Phosphatidic Acid)IBA
12/2003 - 10/2003
1AntigensIBA
11/2014
1Tumor Viral Antigens (Large T Antigen)IBA
11/2014
1Macrophage Colony-Stimulating FactorIBA
11/2010
1LipopolysaccharidesIBA
11/2010
1Pharmaceutical PreparationsIBA
11/2006
1Imatinib Mesylate (Gleevec)FDA Link
11/2006
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
11/2006
1EnzymesIBA
08/2006
1Proteins (Proteins, Gene)FDA Link
08/2006
1Small Interfering RNA (siRNA)IBA
10/2005
1Monoclonal AntibodiesIBA
07/2005
1ThymidineIBA
07/2005
1CaspasesIBA
07/2005
1Bortezomib (Velcade)FDA Link
04/2005
1DiaminesIBA
10/2003
1TriazinesIBA
10/2003

Therapy/Procedure

3Therapeutics
08/2006 - 10/2003